AbbVie Ends Partnership With BioArctic in Parkinson’s Disease
Summary : AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement…
Summary : AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement…
Summary : AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic…
Summary : BDR Pharma, the Mumbai-based drugmaker that raised around ₹750 crore earlier this year from Renuka Ramnath-led private equity (PE) fund…
Summary : AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at…
Summary : British biotech company Scancell has expanded its research and development capabilities at one of the UK’s leading parks for science…
Summary : Chicago-based AbbVie has been making major decisions with company-wide impacts. The therapeutic company appears to be making changes that will…
Synopsis: GlaxoSmithKline has voluntarily paused activities in its Phase III GRACE trial on an experimental maternal vaccine for respiratory syncytial virus (RSV).…
Summary : The DTAB has approved a list of OTC drugs which includes medicines like antifungal infections, analgesics (pain killers), cough syrups,…
Summary : Vigabatrin is used to treat babies, one month to two years old with infantile spasms. Zydus has received final approval…
Summary : -The partnership between Oxford University and SEEQC promises to accelerate the use of quantum computing within pharmaceutical research in order…